創傷ケア生物学的製剤市場 : 2027年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年6月

創傷ケア生物学的製剤市場 : 製品(生物学的皮膚代替物、局所薬剤)、創傷タイプ[潰瘍(糖尿病性足、静脈、圧迫潰瘍)、外科的、外傷性創傷、火傷]、エンドユーザー(病院、ASC、火傷センター)– 2027年までの世界予測
Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

ページ数 174
図表数 214
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global wound care biologics market is valued at an estimated USD 1.8billion in 2022 and is projected to reach USD 2.4billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such asthe growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market.

“The biological skin substitutes segment accounted for the highest growth rate in thewound care biologicsmarket, by product, during the forecast period”
The wound care biologics market is segmented into biological skin substitutes and topical agents. The biological skin substitutes is expected to register the highest growth rate during the forecast period. Factors such as the increasing burden of surgical & traumatic woundsand the increase in burn injuries arecontributing to the growth of this segment.
“Hospitalssegment accounted for the highest CAGR”
Based on end users, the wound care biologics market is segmented into hospitals, ambulatory surgery centers, and burn care centers & wound clinics. Hospitals segment is expected to register the highest CAGR during the forecast period. Extended hospital stays or readmissions of patients with chronic conditions have increased the adoption of various wound care biologic products. The increasing incidence of hospital-acquired wounds is a key growth driver for this market segment. Also, the adoption of wound care biologic products is higher in hospitals, owing to their higher purchasing power, highly skilled healthcare professionals, and access to technologically developed surgical facilities.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global wound care biologics market is segmented into five regions – North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to witness the highest growth in the wound care biologics market during the forecast period. The high growth in this region can primarily be attributed to the increasing prevalence of diabetes, rising healthcare spending, growing per capita income, the expansion of private-sector hospitals to rural areas in various APAC countries, increasing medical tourism, and the presence of high-growth markets.The low labor costs and favorable regulatory environment in the region are also expected to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• Smith & Nephew plc (UK)
• Organogenesis Inc. (US)
• MIMEDX (US)
• Integra LifeSciences (US)
• Stryker Corporation (US)
• Mölnlycke Health Care AB (Sweden)
• Vericel Corporation (US)
• Bioventus LLC (US)
• Anika Therapeutics, Inc. (US)
• AbbVie Inc. (US)
• Kerecis (Iceland)
• Marine Polymer Technologies, Inc. (US)
• Merakris Therapeutics (US)
• PolyMedics Innovations GmbH (Germany)
• FibrohealWoundcarePvt. Ltd. (India)
• Anamay Biotech, Inc. (India)
• Virchow Biotech Private Limited (India)
• Medline Industries, LP (US)
• Tides Medical (US)
• Viscus Biologics LLC (US)
• Stability Biologics (US)
• MTF Biologics (US)
• Skye Biologics Holdings, LLC (US)
• AlloSource (US)
• SurgiLogix (US)

Research Coverage:
This report provides a detailed picture of the global wound care biologics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, wound type, end user,and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall wound care biologics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, and opportunities.


目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 WOUND CARE BIOLOGICS MARKET
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 31)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 3: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 41)
FIGURE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2022 VS. 2027 (USD MILLION)
FIGURE 9 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2022 VS. 2027 (USD MILLION)
FIGURE 10 WOUND CARE BIOLOGICS MARKET, BY END USER,  2022 VS. 2027 (USD MILLION)
FIGURE 11 WOUND CARE BIOLOGICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. – 44)
4.1 WOUND CARE BIOLOGICS MARKET OVERVIEW
FIGURE 12 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS
4.2 WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
FIGURE 13 BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 2027
FIGURE 14 ULCERS SEGMENT DOMINATES MARKET
4.4 WOUND CARE BIOLOGICS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 15 HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS
4.5 WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of diseases & conditions affecting wound healing capabilities
5.2.1.1.1 Growing geriatric population
5.2.1.1.2 Increasing prevalence of diabetes and target conditions
FIGURE 18 PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION,  2021 VS. 2045 (MILLION CASES)
TABLE 1 TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
TABLE 2 LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS
5.2.1.1.3 Increasing number of surgical procedures across the globe
5.2.1.1.4 Increasing number of traumatic wounds
TABLE 3 PREVALENCE OF ROAD ACCIDENTS
5.2.1.2 Increasing incidence of burn injuries
5.2.1.3 Innovations in wound care biologics
5.2.2 MARKET RESTRAINTS
5.2.2.1 High cost of wound care biologic products
TABLE 4 AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018)
5.2.2.2 Risk of skin substitute failure
TABLE 5 COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)
5.2.3 OPPORTUNITIES
5.2.3.1 Growth potential of emerging economies
TABLE 6 STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC
5.2.3.2 3D skin printing
5.3 IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET

6 WOUND CARE BIOLOGICS MARKET, BY PRODUCT (Page No. – 57)
6.1 INTRODUCTION
TABLE 7 WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
6.2 BIOLOGICAL SKIN SUBSTITUTES
TABLE 9 KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET
TABLE 10 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017–2020 (USD MILLION)
TABLE 11 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021–2027 (USD MILLION)
TABLE 12 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2017–2020 (USD MILLION)
TABLE 13 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2021–2027 (USD MILLION)
6.2.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS
6.2.1.1 High efficacy of human donor tissue-derived products to support market demand
TABLE 14 KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET
TABLE 15 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,  2017–2020 (USD MILLION)
TABLE 16 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,  2021–2027 (USD MILLION)
6.2.2 ACELLULAR ANIMAL-DERIVED PRODUCTS
6.2.2.1 Recognition of the importance of ECM in wound treatment has led to the development of acellular wound care biologics
TABLE 17 KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET
TABLE 18 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,  2017–2020 (USD MILLION)
TABLE 19 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,  2021–2027 (USD MILLION)
6.2.3 BIOSYNTHETIC PRODUCTS
6.2.3.1 Increased bioburden of infected wounds to stimulate market growth
TABLE 20 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 21 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3 TOPICAL AGENTS
6.3.1 INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH
TABLE 22 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2017–2020 (USD MILLION)
TABLE 23 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2021–2027 (USD MILLION)

7 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE (Page No. – 67)
7.1 INTRODUCTION
TABLE 24 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 25 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 ULCERS
TABLE 26 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 27 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION, 2021–2027 (USD MILLION)
TABLE 28 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE, 2017–2020 (USD MILLION)
TABLE 29 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE, 2021–2027 (USD MILLION)
7.2.1 DIABETIC FOOT ULCERS
7.2.1.1 Increasing prevalence of diabetes to drive market growth
TABLE 30 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 31 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.2 VENOUS ULCERS
7.2.2.1 Rising prevalence of obesity to drive market growth
TABLE 32 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 33 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.3 PRESSURE ULCERS
7.2.3.1 Growing geriatric population to drive market growth
TABLE 34 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 35 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.4 OTHER ULCERS
TABLE 36 COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS
TABLE 37 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,  2017–2020 (USD MILLION)
TABLE 38 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,  2021–2027 (USD MILLION)
7.3 SURGICAL & TRAUMATIC WOUNDS
7.3.1 RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
TABLE 39 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017–2020 (USD MILLION)
TABLE 40 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021–2027 (USD MILLION)
7.4 BURNS
7.4.1 HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
TABLE 41 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION, 2017–2020 (USD MILLION)
TABLE 42 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION, 2021–2027 (USD MILLION)

8 WOUND CARE BIOLOGICS MARKET, BY END USER (Page No. – 80)
8.1 INTRODUCTION
TABLE 43 WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 44 WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
8.2 HOSPITALS
8.2.1 INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH
TABLE 45 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,  2017–2020 (USD MILLION)
TABLE 46 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,  2021–2027 (USD MILLION)
8.3 AMBULATORY SURGERY CENTERS
8.3.1 GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT
TABLE 47 NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS
TABLE 48 PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US
TABLE 49 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 50 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2027 (USD MILLION)
8.4 BURN CARE CENTERS & WOUND CLINICS
8.4.1 RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH
TABLE 51 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2017–2020 (USD MILLION)
TABLE 52 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2021–2027 (USD MILLION)

9 WOUND CARE BIOLOGICS MARKET, BY REGION (Page No. – 87)
    9.1 INTRODUCTION
TABLE 53 WOUND CARE BIOLOGICS MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 54 WOUND CARE BIOLOGICS MARKET, BY REGION, 2021–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT
TABLE 55 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,  2017–2020 (USD MILLION)
TABLE 56 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,  2021–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
TABLE 58 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2021–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 60 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2017–2020 (USD MILLION)
TABLE 62 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2021–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing prevalence of diabetes and non-healing foot ulcers to support the uptake of wound biologics products
TABLE 63 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 64 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 65 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 66 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 67 US: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 68 US: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising geriatric patient pool to drive market growth for wound biologics in Canada
TABLE 69 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
TABLE 70 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 71 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 72 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 73 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 74 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 75 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3 EUROPE
TABLE 76 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 77 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 78 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 79 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 80 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 81 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 82 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 83 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.1 UK
9.3.1.1 Increasing incidence of venous ulcers to drive the market growth
TABLE 84 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 85 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 86 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 87 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 88 UK: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 89 UK: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 The large diabetic population in Germany supports the uptake of wound biologics in Germany
TABLE 90 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 91 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 92 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 93 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 94 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,  2017–2020 (USD MILLION)
TABLE 95 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,  2021–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising government support to drive the demand for wound care biologics products in France
TABLE 96 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 97 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 98 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 99 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 100 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 101 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.4 REST OF EUROPE
TABLE 102 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 103 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 104 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 105 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 106 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 107 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT
TABLE 108 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,  2017–2020 (USD MILLION)
TABLE 109 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,  2021–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
TABLE 111 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2021–2027 (USD MILLION)
TABLE 112 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 113 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,  2017–2020 (USD MILLION)
TABLE 115 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,  2021–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Increasing incidence of DFUs to propel the market growth
TABLE 116 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 117 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 118 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 119 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 120 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 121 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Growing geriatric population to drive the adoption of wound care products
TABLE 122 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 123 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 124 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 125 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 126 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 127 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growing medical tourism in the country to support the market growth for wound biologics
TABLE 128 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 129 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 130 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 131 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 132 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 133 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 134 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 135 ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 136 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
TABLE 137 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
TABLE 138 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 139 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH
TABLE 140 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
TABLE 141 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2021–2027 (USD MILLION)
TABLE 142 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 143 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 144 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2017–2020 (USD MILLION)
TABLE 145 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2021–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS
TABLE 146 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 147 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
TABLE 149 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
TABLE 150 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. – 130)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET
TABLE 152 OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES
10.3 MARKET SHARE ANALYSIS
10.3.1 WOUND CARE BIOLOGICS MARKET
FIGURE 21 WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 153 WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION
10.4 COMPANY EVALUATION QUADRANT
10.4.1 LIST OF EVALUATED VENDORS
10.4.2 STARS
10.4.3 EMERGING LEADERS
10.4.4 PERVASIVE PLAYERS
10.4.5 PARTICIPANTS
FIGURE 22 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
FIGURE 23 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
10.6 COMPETITIVE SCENARIO
10.6.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 154 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
10.6.2 DEALS
TABLE 155 KEY DEALS
10.6.3 OTHER DEVELOPMENTS
TABLE 156 OTHER DEVELOPMENTS

11 COMPANY PROFILES (Page No. – 139)
11.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats)*
11.1.1 SMITH & NEPHEW PLC
TABLE 157 SMITH & NEPHEW PLC: BUSINESS OVERVIEW
FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)
11.1.2 ORGANOGENESIS INC.
TABLE 158 ORGANOGENESIS INC.: BUSINESS OVERVIEW
FIGURE 25 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021)
11.1.3 MIMEDX
TABLE 159 MIMEDX: BUSINESS OVERVIEW
FIGURE 26 MIMEDX: COMPANY SNAPSHOT (2021)
11.1.4 INTEGRA LIFESCIENCES
TABLE 160 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 27 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)
11.1.5 STRYKER CORPORATION
TABLE 161 STRYKER CORPORATION: BUSINESS OVERVIEW
FIGURE 28 STRYKER CORPORATION: COMPANY SNAPSHOT (2021)
11.1.6 MÖLNLYCKE HEALTH CARE AB
TABLE 162 MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW
FIGURE 29 MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021)
11.1.7 VERICEL CORPORATION
TABLE 163 VERICEL CORPORATION: BUSINESS OVERVIEW
FIGURE 30 VERICEL CORPORATION: COMPANY SNAPSHOT (2021)
11.1.8 ANIKA THERAPEUTICS, INC.
TABLE 164 ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW
FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021)
11.1.9 BIOVENTUS LLC
TABLE 165 BIOVENTUS LLC: BUSINESS OVERVIEW
FIGURE 32 BIOVENTUS LLC: COMPANY SNAPSHOT (2021)
11.1.10 ABBVIE INC.
TABLE 166 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2021)
11.1.11 KERECIS
TABLE 167 KERECIS: BUSINESS OVERVIEW
11.1.12 MARINE POLYMER TECHNOLOGIES, INC.
TABLE 168 MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 MERAKRIS THERAPEUTICS
TABLE 169 MERAKRIS THERAPEUTICS: COMPANY OVERVIEW
11.2.2 POLYMEDICS INNOVATIONS GMBH
TABLE 170 POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW
11.2.3 FIBROHEAL WOUNDCARE PVT. LTD.
TABLE 171 FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW
11.2.4 ANAMAY BIOTECH, INC.
TABLE 172 ANAMAY BIOTECH, INC.: COMPANY OVERVIEW
11.2.5 VIRCHOW BIOTECH PRIVATE LIMITED
TABLE 173 VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW
11.2.6 MEDLINE INDUSTRIES, LP
TABLE 174 MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW
11.2.7 TIDES MEDICAL
TABLE 175 TIDES MEDICAL: COMPANY OVERVIEW
11.2.8 VISCUS BIOLOGICS LLC
TABLE 176 VISCUS BIOLOGICS LLC: COMPANY OVERVIEW
11.2.9 STABILITY BIOLOGICS
TABLE 177 STABILITY BIOLOGICS: COMPANY OVERVIEW
11.2.10 MTF BIOLOGICS
TABLE 178 MTF BIOLOGICS: COMPANY OVERVIEW
11.2.11 SKYE BIOLOGICS HOLDINGS, LLC
TABLE 179 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
11.2.12 ALLOSOURCE
TABLE 180 ALLOSOURCE: COMPANY OVERVIEW
11.2.13 SURGILOGIX
TABLE 181 SURGILOGIX: COMPANY OVERVIEW
*Details on Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX (Page No. – 174)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com